Trial Profile
Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects With Severe Asthma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Navarixin (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
- 14 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 26 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Jan 2010 Planned initiation date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.